ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Berberine inhibits NLRP3 inflammasome activation by regulating mTOR/ mtROS axis to alleviate diabetic cardiomyopathy

Zhong, Changsheng; Xie, Yilin; Wang, Huifang; Chen, Wenxian; Yang, Zhenbo; Zhang, Lei; Deng, Qin; Cheng, Ting; Li, Mengyang; Ju, Jin; Liu, Yanyan*; Liang, Haihai*哈尔滨医科大学
European Journal of Pharmacology2024-2-5DOI: 10.1016/j.ejphar.2023.176253
10阅读
引用收藏
分享

摘要

Diabetes cardiomyopathy (DCM) refers to myocardial dysfunction and disorganization resulting from diabetes. In this study, we investigated the effects of berberine on cardiac function in male db/db mice with metformin as a positive control. After treatment for 8 weeks, significant improvements in cardiac function and a reduction in collagen deposition were observed in db/db mice. Furthermore, inflammation and pyroptosis were seen to decrease in these mice, as evidenced by decreased expressions of p-mTOR, NOD-like receptor thermal protein domain associated protein 3 (NLRP3), IL-1 beta, IL-18, caspase-1, and gasdermin D (GSDMD). In vitro experiments on H9C2 cells showed that glucose exposure at 33 mmol/L induced pyroptosis, whereas berberine treatment reduced the expression of p-mTOR and NLRP3 inflammasome components. Moreover, berberine treatment was seen to inhibit the generation of mitochondrial reactive oxygen species (mtROS) and effectively improve cell damage in high glucose-induced H9C2 cells. The mTOR inhibitor, Torin-1, showed a therapeutic effect similar to that of berberine, by reducing the expression of NLRP3 inflammasome components and inhibiting mtROS gen-eration. However, the activation of mTOR by MHY1485 partially nullified berberine's protective effects during high glucose stress. Collectively, our study reveals the mechanism that berberine regulates the mTOR/mtROS axis to inhibit pyroptosis induced by NLRP3 inflammasome activation, thereby alleviating DCM.

学科与关键词

关键词
BerberinemTORmtROSNLRP3 inflammasomeDiabetic cardiomyopathy
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
European Journal of Pharmacology
发表日期
2024-02-05
卷期
第 964 卷
页码
176253
DOI
10.1016/j.ejphar.2023.176253
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82330011, 32171127]; Scientific Fund Project of Heilongjiang Province [JQ 2022H001]

作者

  • Z

    Zhong, Changsheng (第一作者)

    shenzhen univ

  • X

    Xie, Yilin

    shenzhen univ

查看全部 12 位作者收起作者
  • W

    Wang, Huifang

    shenzhen univ

  • C

    Chen, Wenxian

    shenzhen univ

  • Y

    Yang, Zhenbo

    shenzhen univ

  • Z

    Zhang, Lei

    shenzhen univ

  • D

    Deng, Qin

    shenzhen univ

  • C

    Cheng, Ting

    shenzhen univ

  • L

    Li, Mengyang

    shenzhen univ

  • J

    Ju, Jin

    shenzhen univ

  • L

    Liu, Yanyan (通讯)

    zhuhai peoples hosp

  • L

    Liang, Haihai (通讯)

    harbin med univ · zhuhai peoples hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417